Objective: To determine the frequency of new-onset hypertension in patients with Rheumatoid arthritis taking leflunomide, in comparison with methotrexate in Asian setting.
Material and Methods: Perspective case-control study was conducted in 2014 in a tertiary care hospital located in Karachi, Pakistan. Adult patients, having rheumatoid arthritis were randomly prescribed leflunomide or methotrexate. Patients having chronic hypertension, proteinuria and chronic kidney disease were excluded. Patients were monthly followed for blood pressure and heart rate measurements. Hypertension was defined using JNC 7 criteria.
Results: Out of 144 patients enrolled, 80 patients received Leflunomide while 64 were started on methotrexate. Mean systolic blood pressure in leflunomide group at the start and at the end of study was 108.5 and 135.4mmHg, respectively while in methotrexate group, mean systolic BP was 109.8 and 110.5 mmhg, respectively. After one year follow up, 33 out of 80 (41%) patients were receiving leflunomide had pre-hypertension or hypertension, while only 3 out of 64 patients (4.7%) were receiving methotrexate had hypertension.
Conclusion: Risk of developing hypertension in patient receiving Leflunomide is much higher in Asian population like Pakistan as compared to western population.
Keywords: Hypertension, leflunomide, rheumatoid arthritis, methotrexate, patients, proteinuria.
[http://dx.doi.org/10.1016/j.curtheres.2012.06.001] [PMID: 24653514]
[http://dx.doi.org/10.1002/1529-0131(200109)44:9<1984:AID-ART346>3.0.CO;2-B] [PMID: 11592358]
[http://dx.doi.org/10.1111/j.1756-185X.2010.01586.x] [PMID: 21303481]
Hormone Mediation of Immune Responses in the Progression of Diabetes, Rheumatoid Arthritis and Periodontal Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Gold - Old Drug with New Potentials
Current Medicinal Chemistry Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Catecholamines, Sympathetic Innervation and Immunity: Role in Experimental and Rheumatoid Arthritis
Letters in Drug Design & Discovery Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Ω-3 Polyunsaturated Fatty Acids and Immune-Mediated Diseases: Inflammatory Bowel Disease and Rheumatoid Arthritis
Current Pharmaceutical Design p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis
Mini-Reviews in Medicinal Chemistry Update on Therapeutic Approaches for Rheumatoid Arthritis
Current Medicinal Chemistry Development of Low Molecular Weight CXCR4 Antagonists by Exploratory Structural Tuning of Cyclic Tetra- and Pentapeptide-Scaffolds Towards the Treatment of HIV Infection, Cancer Metastasis and Rheumatoid Arthritis
Current Medicinal Chemistry Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Alternative Use of Bisphosphonate Therapy for Rheumatic Disease
Current Pharmaceutical Design The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors
Current Medicinal Chemistry The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine TLR7/9 Antagonists as Therapeutics for Immune-Mediated Inflammatory Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Non-Pharmacologic Treatment Options in Rheumatologic Disease
Current Rheumatology Reviews